On July 13, 2026, Indonesia's Food and Drug Authority (BPOM) revoked the distribution permits (izin edar) of 14 cosmetic products and ordered a temporary halt to their production, distribution and import, after routine Q2 2026 post-market surveillance found them to contain prohibited or dangerous ingredients. The action, set out in press release HM.01.2.1.07.26.192, targets both online and offline sales channels and follows laboratory confirmation that every listed product fails Indonesia's cosmetics safety requirements.
Of the 14 products, 11 are locally made under contract production, one is imported, and two were placed on the market without any izin edar at all. BPOM head Taruna Ikrar confirmed the sweep was conducted jointly with all of the agency's technical units across Indonesia. The full product list is published in the official annex to the press release.
Which products lost their permits, and what must manufacturers do now?
Every product on the list has had its izin edar revoked and is subject to a penghentian sementara kegiatan (PSK), meaning production, distribution and import must stop immediately. BPOM is also raiding production facilities and retail outlets, including online sellers, and tracing the production and distribution chains to prevent the same products re-entering the market. Contract manufacturers whose clients' products appear on the list should treat this as a formulation and supply-chain audit trigger, not a one-off recall.
What prohibited ingredients did BPOM find, and why do they matter?
BPOM identified six prohibited or dangerous substances across the 14 products. Each carries a documented health risk that places it outside the permitted ingredient annexes of Indonesia's cosmetics regime (PerBPOM 25/2025, implementing the ASEAN Cosmetic Directive).
| Ingredient | Found as | Key health risk |
|---|---|---|
| Retinoic acid | asam retinoat | Skin drying and burning; teratogenic risk for pregnant women |
| Hydroquinone | hidrokuinon | Hyperpigmentation, ochronosis, cornea and nail discoloration |
| Clobetasol propionate | klobetasol propionat | Skin atrophy, permanent atopic eczema, pustular psoriasis |
| Mometasone furoate | mometason furoat | Skin atrophy |
| Red dye K10 | pewarna merah K10 | Cancer risk, liver function impairment |
| Mercury | merkuri | Skin irritation, dark spots, kidney damage |
The corticosteroids (clobetasol and mometasone) and hydroquinone are recurring findings in Indonesian skin-lightening products, and mercury remains a persistent contaminant in the same category. Their presence signals a formulation control failure that BPOM treats as a safety violation, not a labelling defect.
What penalties apply under Health Law No. 17/2023?
Circulating cosmetics that contain prohibited or dangerous ingredients breaches Article 435(1) in conjunction with Article 138(2) of Law No. 17/2023 on Health (UU 17/2023), the umbrella law that consolidated Indonesia's health-product regime. The exposure is criminal as well as administrative: offenders face up to 12 years imprisonment or a fine of up to Rp 5 billion (IDR 5.000.000.000). The two products without an izin edar carry the additional offence of unauthorised marketing.
How does this fit BPOM's post-market surveillance regime?
The sweep is a routine quarterly output of BPOM's post-market surveillance (pengawasan pasca pasar) for cosmetics, governed by PerBPOM 12/2023 alongside the notification regime in PerBPOM 21/2022 and the CPKB good-manufacturing certification in PerBPOM 8/2026. The word "kembali" (again) in BPOM's own title signals a recurring enforcement cycle, not a one-time event: compliance leads should expect another tranche in Q3 2026. BPOM also urged consumers to apply its Cek KLIK check (Kemasan, Label, Izin edar, Kedaluwarsa) before buying, especially on digital platforms where the surveilled products were sourced.
Obsidian's continuous, per-jurisdiction monitoring surfaces enforcement actions like this the moment BPOM publishes them, before a quarterly sweep catches a formulation off-guard.
Follow this topic in real time with a free monitoring job
Next steps: cross-check the annex list against your active SKUs and contract-manufacturing clients, verify that no prohibited ingredient has entered your supply chain through a raw-material substitution, confirm every product holds a valid izin edar, and brief formulation and QA teams ahead of the expected Q3 sweep.
